HepaLife Announces Appointment of Dr. Christopher W. Kemp, Vice President of Research & Development

Successful biologics entrepreneur and researcher joins HepaLife; brings three decades of experience with cell biology, bioreactors, and vaccines - key to development of HepaLife's novel, cell-based technologies.

Boston, MA – January 22, 2008 – HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625), developer of the first-of-its-kind artificial liver device, today announced the appointment of its Vice President, Research & Development, Dr. Christopher W. Kemp, a proven cell biology research scientist and successful entrepreneur with over thirty years of experience.

During his 17 year tenure as a cell biology researcher, Dr. Kemp served in various capacities, including a decade of award-winning service at the National Institutes of Health where he received four awards for his contribution.  Ultimately, Dr. Christopher W. Kemp founded and operated his own privately-held cell biologics research firm for 15 years, which was successfully acquired in 2006 by a life sciences research group with $100 million in equity funding commitments.

“Chris brings us a unique set of skills, where in addition to his keen business sense he is an expert in cell-culture process development and documentation, bioreactor design and operation, and serum-free medium development.  Dr. Kemp’s particular know-how of bioreactors, cells, and process development, directly contributes to the ongoing development of our entire spectrum of cell-based technologies,” explained Mr. Frank Menzler, President and CEO of HepaLife. 

Effective February 1, 2008. Dr. Kemp will be responsible for HepaLife’s global research efforts and will play a key role in developing technology strategy plans for the Company’s portfolio of cell-based technologies, including: the first-of-its kind artificial liver device, in-vitro toxicology testing platforms, and a novel vaccine production system.

“I am excited to join HepaLife’s team of dedicated professionals, and to support the Company’s mission to develop a bioartificial liver device, potentially helping thousands of patients suffering from liver disease worldwide,” stated Dr. Christopher W. Kemp. “HepaLife has an excellent array of technologies, and I look forward to implementing and leading scientific best practices in order to support the development and growth of our company.”

“Chris brings extensive scientific, operational and business experience to HepaLife. We very much look forward to his contribution as Vice President of Research and Development,” concluded Mr. Menzler.

Christopher W. Kemp, Ph.D.:

Dr. Christopher W. Kemp has over thirty years of experience in the development of cellular based processes. For the past fifteen years Dr. Kemp has served as President of Kemp Biotechnologies, Inc., a private contract manufacturing organization servicing the pharmaceutical research market.

Dr. Kemp founded Kemp Biotechnologies, Inc. in 1992, subsequently acquired in 2006 by Pelican Life Sciences, a life sciences research company backed by $100 million in equity capital commitments. Kemp Biotechnologies specialized in the scale-up of cellular based expression systems using novel bioreactor technologies.

Prior to 1992, Dr. Christopher W. Kemp developed serum-free animal cell culture media formulation for BioWhittaker, Inc. for seven years, and previously at the National Institutes of Health in Bethesda, MD worked on process development applications for the production of human vaccines, where he received four awards during his decade-long tenure.

Dr. Christopher W. Kemp earned his Bachelor of Science degree in Microbiology from University of Maryland ( College Park, MD), and a Master of Science degree in Biomedical Science from Hood College (Frederick Park, MD).  He completed his PhD in Microbiology at George Washington University ( Washington, DC).

ABOUT HEPALIFE TECHNOLOGIES, INC.

Based in Boston, Massachusetts, HepaLife Technologies, Inc. (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) is a developer of cell-based medical technologies addressing prevalent human health concerns.

Current cell-based technologies under development by HepaLife include 1) the first-of-its-kind artificial liver device, 2) proprietary in-vitro toxicology and pre-clinical drug testing platforms, and 3) novel cell-culture based vaccine production methods for the manufacture of vaccines against H5N1 avian influenza and other viruses.

For additional information, please visit www.hepalife.com.

To receive future press releases via email, please visit:
http://www.hepalife.com/investor-alerts.php

To view the full HTML text of this release, please visit:
http://hepalife.com/press_releases/20080122-1.html.php

#      #      #      #

Legal Notice Regarding Forward-Looking Statements

No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that HepaLife will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company makes no commitment to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.